Iovance Biotherapeutics, based in San Carlos, California, specializes in cell therapies for cancer, focusing on its lead product, Amtagvi, for melanoma treatment. The company employs 557 people and went public in 2008.
Iovance Biotherapeutics (IOVA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Iovance Biotherapeutics's actual EPS was -$0.36, missing the estimate of -$0.24 per share, resulting in a -47.48% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
